secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001104659-25-098991
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris holds R&D Day presenting I&I pipeline; no specific data disclosed in filing
--------------------------------------------------------------------------------

- R&D Day held Oct 14, 2025, focusing on immunology and inflammation (I&I) therapeutic franchises.
- Presentation furnished as Exhibit 99.1; available on Investor Relations section of company website.
- No financial results, clinical data, or guidance changes were included in the 8-K or exhibit snippet.
- Company continues to develop pipeline for gaps in I&I diseases; no material updates provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465925098991/0001104659-25-098991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465925098991/acrs-20251014x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-098991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer